Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma

Chemotherapy

Volumn 50, Issue 6, 2004, Pages 279-282

  Oguri, Tetsuya ^a   Achiwa, Hiroyuki ^a   Kato, Daisuke ^a   Maeda, Hiroyoshi ^a   Niimi, Takashi ^a   Sato, Shigeki ^a   Ueda, Ryuzo ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Docetaxel; Second line chemotherapy; Thymic carcinoma

Indexed keywords

DOCETAXEL; ETOPOSIDE; IFOSFAMIDE; NEDAPLATIN;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; NEUTROPENIA; PRIORITY JOURNAL; SHOULDER PAIN; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; THYMUS CANCER; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; CERVICAL VERTEBRAE; FEMALE; HUMANS; MEDIASTINAL NEOPLASMS; MEDIASTINUM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; SPINAL NEOPLASMS; TAXOIDS; THYMOMA; THYMUS NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 11244349791     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082626     Document Type: Article

References (13)

1. Liu H-C, Hsu W-H, Chen Y-J, Chan Y-J, Wu Y-C, Huang B-S, Huang M-H: Primary thymic carcinoma. Ann Thorac Surg 2002;73:1076-1081.
2. Ogawa K, Toita T, Uno T, Fuwa N, Kakinohara Y, Kamata M, Koja K, Kinjo T, Adachi G, Murayama S: Treatment and prognosis of thymic carcinoma: A retrospective analysis of 40 cases. Cancer 2002;94:3115-3119.
3. Chahinian AP: Chemotherapy of thymomas and thymic carcinomas. Chest Surg Clin N Am 2001;11:447-456.
4. Masaoka A, Monden Y, Nakahara K, Tanioka T: Follow-up study of thymomas with special reference to their clinical stage. Cancer 1981;48:2485-2492.
5. Kitami A, Suzuki T, Kamio Y, Suzuki S: Chemotherapy of thymic carcinoma: Analysis of seven cases and review of the literature. Jpn J Clin Oncol 2001;31:601-604.
6. Loehrer PJ Sr, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR Jr, Livingston R, Johnson DH: Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: An intergroup trial. Cancer 2001;91:2010-2015.
7. Palmieri G, Montella L, Martignetti A, Muto P, Di Vizio D, De Chiara A, Lastoria S: Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 2002;94:1414-1420.
8. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C: Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001;47(suppl 2):30-39.
9. Jenkins SA, Kynaston HG, Davies ND, Baxter JN, Nott DM: Somatostatin analogs in oncology: A look to the future. Chemotherapy 2001;47(suppl 2):162-196.
10. Shintani Y, Ohta M, Hazama K, Miyoshi S, Kagisaki K, Matsuda H: Thymic carcinoma successfully resected with superior vena cava after chemoradiotherapy. Jpn J Thorac Cardiovasc Surg 2001;49:717-721.
11. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
12. Nabholtz J-M, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A, Aapro M: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413-1424.
13. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H, Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35:1194-1201.